Research Progress and Challenges of Lipid Nanocarriers Mediated Sirna Delivery for Cancer Therapy
DOI:
https://doi.org/10.54097/xb5npk11Keywords:
Small interfering RNA (siRNA); Cancer treatment; Gene silencing; Delivery system; Lipid nanocarriers.Abstract
Cancer remains a major global health burden, and traditional treatment methods have limitations. Precision medicine, especially the use of small interfering RNA (siRNA), offers new hope. siRNA can specifically silence cancer - related genes, but its clinical application is hindered by multiple challenges, such as instability, poor cellular uptake, and potential off - target effects. Lipid - based delivery systems, including cationic liposomes, anionic and neutral liposomes, stable nucleic acid - lipid particles (SNALPs), and lipid nanoparticles (LNPs), have emerged as promising solutions. This review focuses on the role of siRNA in cancer treatment, its mechanism, and potential targets. It also comprehensively analyzes the lipid - based delivery systems, including their delivery strategies, advantages, and disadvantages. By exploring these aspects, this paper aims to provide valuable insights for future research and clinical applications in siRNA - based cancer therapies.
Downloads
References
[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: A Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
[2] Ganesh K, Massague J. Targeting metastatic cancer. Nat Med. 2021;27(1):34–44. doi:10.1038/s41591-020-01195-4
[3] Dias MP, Moser SC, Ganesan S, Jonkers J. Understanding and overcoming resistance to PARP inhibitors in cancer therapy. Nat Rev Clin Oncol. 2021;18(12):773–791. doi:10.1038/s41571-021-00532-x
[4] Nussinov R, Tsai CJ, Jang H. Anticancer drug resistance: an update and perspective. Drug Resist Updat. 2021; 59:100796. doi: 10.1016/j.drup.2021.100796
[5] Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):101. doi:10.1038/s41392-020-0207-x
[6] Downward J. RNA interference. BMJ. 2004;328(7450):1245 - 1248. doi:10.1136/bmj.328.7450.1245
[7] Shakil S, Baig MH, Tabrez S, et al. Molecular and enzoinformatics perspectives of targeting Polo - like kinase 1 in cancer therapy. Semin Cancer Biol. 2019; 56:47 - 55. doi: 10.1016/j.semcancer.2017.11.004
[8] Cho H, Kaelin WG. Targeting HIF2 in clear cell renal cell carcinoma. Cold Spring Harb Symp Quant Biol. 2016; 81:113 - 121. doi:10.1101/sqb.2016.81.030833
[9] Martinez - Outschoorn UE, Peiris - Pages M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14(1):11 - 31. doi:10.1038/nrclinonc.2016.60
[10] Buyens K, De Smedt SC, Braeckmans K, et al. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J Control Release. 2012;158(3):362–370. doi: 10.1016/j.jconrel.2011.10.009
[11] Mainini F, Eccles MR. Lipid and polymer - based nanoparticle siRNA delivery systems for cancer therapy. Molecules. 2020;25(11):2692. doi:10.3390/molecules25112692
[12] Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol. 2003;327(4):761–766. doi:10.1016/S0022 - 2836(03)00181 - 5
[13] Balgobind A, Daniels A, Ariatti M, Singh M. HER2/neu oncogene silencing in a breast cancer cell model using cationic lipid - based delivery systems. Pharmaceutics. 2023;15(4):1190. doi:10.3390/pharmaceutics15041190
[14] Jarallah SJ, Aldossary AM, Tawfik EA, et al. GL67 lipid - based liposomal formulation for efficient siRNA delivery into human lung cancer cells. Saudi Pharm J. 2023;31(7):1139–1148. doi: 10.1016/j.jsps.2023.05.017
[15] Santel A, Aleku M, Keil O, et al. A novel siRNA - lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 2006;13(16):1222–1234. doi:10.1038/sj.gt.3302777
[16] Landen CN Jr, Chavez - Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005;65(15):6910–6918. doi:10.1158/0008 - 5472.CAN - 05 - 0530
[17] Sahu R, Jha S, Pattanayak SP. Therapeutic silencing of mTOR by systemically administered siRNA - loaded neutral liposomal nanoparticles inhibits DMBA - induced mammary carcinogenesis. Br J Cancer. 2022;127(12):2207–2219. doi:10.1038/s41416 - 022 - 02011 - 1
[18] Ramos - Gonzalez MR, Vazquez - Garza E, Garcia - Rivas G, Rodriguez - Aguayo C, Chavez - Reyes A. Therapeutic effects of WT1 silencing via respiratory administration of neutral DOPC liposomal - siRNA in a lung metastasis melanoma murine model. Noncoding RNA. 2023;9(2). doi:10.3390/ncrna9020021
[19] Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti - HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23(8):1002–1007. doi:10.1038/nbt1122
[20] Ozpolat B, Sood AK, Lopez - Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014; 66:110–116. doi: 10.1016/j.addr.2013.12.008
[21] Judge AD, Robbins M, Tavakoli I, et al. Confirming the RNAi - mediated mechanism of action of siRNA - based cancer therapeutics in mice. J Clin Invest. 2009;119(3):661–673. doi:10.1172/JCI37515
[22] Abdel - Bar HM, Walters AA, Lim Y, et al. An “eat me” combinatory nano - formulation for systemic immunotherapy of solid tumors. Theranostics. 2021;11(18):8738–8754. doi:10.7150/thno.56936
[23] Akinc A, Zumbuehl A, Goldberg M, et al. A combinatorial library of lipid - like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008;26(5):561–569. doi:10.1038/nbt1402
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
